A Preliminary Study of the Complement Component 1q Levels in Predicting the Efficacy of Combined Immunotherapy in Patients with Lung Cancer.

Zhang, Daoming; Li, Yuan; Li, Haoyue; Tang, Tian; Zheng, Yongfa; Guo, Xufeng; Xu, Ximing

Zhang, Daoming; Li, Yuan; Li, Haoyue; Tang, Tian; Zheng, Yongfa; Guo, Xufeng; Xu, Ximing.

Afiliación

Zhang D; Cancer Center, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China.
Li Y; Cancer Center, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China.
Li H; Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China.
Tang T; Cancer Center, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China.
Zheng Y; Cancer Center, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China.
Guo X; Cancer Center, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China.
Xu X; Cancer Center, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China.

Cancer Manag Res ; 13: 7131-7137, 2021.

Article en En | MEDLINE | ID: mdl-34531687

Palabras clave

complement component 1q; efficacy prediction; immunotherapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancer Manag Res Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google